Drew Cronin-Fine joined the Relief team in April 2022 as Executive Director and Head of U.S. Marketing. She is proven leader, with a successful track record of launching numerous products in the rare disease space, and has deep expertise in digital technology, strategic planning and team building. Prior to joining Relief, Ms. Cronin-Fine held numerous positions of increasing responsibility in U.S. Marketing at Intercept Pharmaceuticals, Inc. As Executive Director, she led the U.S. Marketing department for OCALIVA®, indicated for use in primary biliary cholangitis, an orphan liver disease. Before that, she worked at Cubist Pharmaceuticals (subsequently acquired by Merck), most recently serving as Associate Director, U.S. Marketing, where she managed the U.S. market research, market access, and forecasting budget plan for ZERBAXA®, a gram-negative anti-infective drug. Ms. Cronin-Fine holds a Bachelor of Science degree from Brown University, a Master of Business Administration degree from Harvard Business School, and a Master of Science from the Harvard-MIT Division of Health Sciences and Technology.